imb yh 8

Omiloxetine was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.

IMB-YH-8 is an inhibitor of protein kinase B (PknB), inhibiting PknB auto-phosphorylation and the phosphorylation of GarA by PknB in a dose-dependent manner.